The First Report of a Real-world Experience With a PCSK9 Inhibitor in a Large Familial Hyperlipidemia and Very-high-risk Middle Eastern Population-Reference-Cited by-同舟云学术

The First Report of a Real-world Experience With a PCSK9 Inhibitor in a Large Familial Hyperlipidemia and Very-high-risk Middle Eastern Population

Published:2022-10 Issue:10 Volume:44 Page:1297-1309
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Iqbal Sajid,Sabbour Hani Mohamed,Siddiqui Mohsin Sohail,Tikriti Alia Al,Santos Raul D.,Buckley Adam

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference34 articles.

1. PCSK9 inhibitors and cardiovascular disease: Heralding a new therapeutic era. Vol. 26, Current Opinion in Lipidology;Chapman;Lippincott Williams and Wilkins,2015

2. Evolocumab and clinical outcomes in patients with cardiovascular disease;Sabatine;New England Journal of Medicine,2017

3. European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk;Landmesser;European Heart Journal [Internet],2016

4. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines;Arnett;Circulation. NLM (Medline),2019

5. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS);Mach;European Heart Journal [Internet],2020

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness and Safety of Anti-PCSK9 Treatment in Persons with Hyperlipidemia: A Register-Based Cohort Study;2023-07-25

2. Adherence to statin therapy: it seems we know everything, yet we do nothing;European Heart Journal Open;2022-10-26

3. Dual Therapy for Dyslipidemia: When Two May Be Better Than One;Clinical Therapeutics;2022-10